What is Cencora?
Pharmaceutical distribution and services company with ~$309B of FY2025 revenue and enterprise healthcare scale.
- Category
- Pharmaceutical distribution and services
- Headquarters
- Conshohocken, PA
- Founded
- 2001
- Employees
- 46,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: COR; ~$45B market cap
What is Cencora?
Cencora is a public pharmaceutical distribution and services company headquartered in Conshohocken, PA. It reported ~$309B of FY2025 revenue and operates at global enterprise scale.
Cencora operates in pharmaceutical distribution and services with a portfolio spanning U.S. Healthcare Solutions and International Healthcare Solutions. The company reported ~$309B of FY2025 revenue, employs about 46,000+, and trades as NYSE: COR. Its customer base is large, regulated, and relationship-driven, with purchasing decisions shaped by clinical outcomes, compliance, reimbursement, operating leverage, and long-term supply reliability.
The company's scale comes from durable demand in healthcare, recurring consumables or services, installed bases, payer or provider relationships, and disciplined capital allocation. Unlike early-stage software companies, Cencora is evaluated through revenue growth, margins, cash flow, reimbursement exposure, procedure or prescription volume, quality, and regulatory execution.
For sellers, Cencora is not a single buying center. The practical map includes procurement, finance, clinical, IT, security, compliance, operations, supply chain, commercial teams, and business-unit executives. Strong pitches connect directly to patient outcomes, cost-to-serve, risk reduction, revenue capture, uptime, or measurable productivity.
What does Cencora offer?
Cencora offers healthcare products and services across U.S. Healthcare Solutions and International Healthcare Solutions.
- U.S. healthcare solutions· Distribution
- International healthcare solutions· Distribution
- Specialty distribution· Specialty
- Manufacturer services· Biopharma
- World Courier logistics· Logistics
- Market access and consulting· Services
- Animal health distribution· Animal health
How does Cencora make money?
Cencora earns revenue from pharmaceutical distribution, specialty logistics, manufacturer services, market access, consulting, and international healthcare distribution.
Cencora earns revenue from pharmaceutical distribution, specialty logistics, manufacturer services, market access, consulting, and international healthcare distribution. In FY2025, that model produced ~$309B of revenue, showing the scale of the installed base, service footprint, payer/provider contracts, or distribution volume behind the business.
Pricing is negotiated through distribution contracts, manufacturer service agreements, specialty logistics, working-capital terms, fee-for-service programs, and provider or pharmacy network volume. That makes the relevant "pricing tier" for sellers an enterprise contracting motion: account segmentation, compliance review, value analysis, legal terms, security review, reimbursement impact, and multi-year renewal economics.
Growth is driven by a mix of market expansion, procedure or prescription volume, product launches, acquisitions, geographic reach, contract renewals, operational efficiency, and technology adoption. Vendors should expect rigorous procurement, documented ROI, data-security requirements, and evidence that the product can work inside regulated healthcare operations.
Who leads Cencora?
Cencora is led by Bob Mauch, with finance, operations, clinical, technology, and business-unit leaders shaping major enterprise decisions.
- Bob MauchPresident and Chief Executive OfficerCEO since 2024Leads the post-AmerisourceBergen Cencora strategy.
- Jim ClearyExecutive Vice President and Chief Financial OfficerCFO since 2018Finance leader across distribution and international operations.
- Elizabeth CampbellExecutive Vice President and Chief Legal OfficerSenior executive leadershipLegal, compliance, and corporate-governance leader.
- Silvana BattagliaExecutive Vice President and Chief Human Resources OfficerSenior executive leadershipLeads people strategy across the global organization.
How do you contact Cencora's leadership?
Cencora publishes investor-relations, media, supplier, customer, and compliance channels, but it does not publish verified personal executive emails for the listed leaders. Use the public investor-relations route (investor.relations@cencora.com) or official contact forms rather than guessed personal addresses.
investor.relations@cencora.com is a public investor/contact route; personal executive email format not verifiedHow much funding has Cencora raised?
Cencora is a mature public company, not a venture-backed startup. It trades as NYSE: COR, had an approximate ~$45B market capitalization in June 2026, and funds growth through operating cash flow, debt markets, public equity access, and acquisition capacity.
Cencora's capital history is a public-company story rather than a disclosed venture-round history. The relevant milestones are founding in 2001, public-market access, acquisitions, debt capacity, dividends or buybacks where applicable, and reinvestment in regulated healthcare capabilities.
The company reported ~$309B of FY2025 revenue and operates with the financing tools expected of a large public healthcare company. Capital is directed toward product development, clinical evidence, facilities, inventory, technology, acquisitions, compliance, reimbursement capabilities, and shareholder returns depending on the business model.
Seller signal: Cencora has meaningful buying power, but budget access is tied to risk, ROI, compliance, and executive sponsorship. Vendors should map proposals to cost reduction, growth, care quality, automation, supply resilience, cybersecurity, data quality, or measurable operating improvement.
How did Cencora get here?
Cencora grew through founding, public-market scale, product expansion, acquisitions, and healthcare-market execution.
- 2001AmeriSource and Bergen Brunswig mergeThe company forms as AmerisourceBergen.
- 2012World Courier acquiredSpecialty logistics becomes a major capability.
- 2021Alliance Healthcare acquiredInternational distribution scale expands.
- 2023Cencora rebrandAmerisourceBergen becomes Cencora.
- 2024Bob Mauch becomes CEOLeadership transition follows Steven Collis's tenure.
- 2025Fiscal 2025 growthCencora reports higher revenue and adjusted EPS.
Who are Cencora's competitors?
Cencora competes with companies that overlap in customers, budgets, clinical categories, distribution channels, or healthcare services.
- McKessonPharmaceutical distribution, oncology, and healthcare-services competitor.
- Cardinal HealthU.S. drug and medical distribution competitor.
- Henry ScheinHealthcare product distribution competitor.
- Owens & MinorMedical distribution and supply-chain competitor.
- UPS HealthcareHealthcare logistics competitor, especially in specialty and cold chain.
Cencora — frequently asked questions
